LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

A summary of recent health news includes HIV transmission via organ transplants in Brazil, a reconsideration of Eli Lilly's ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...